Citation

Marco EM, Laviola G. J. Psychopharmacol. 2012; 26(1): 150-163.

Affiliation

Department of Animal Physiology (Animal Physiology II), Faculty of Biological Sciences, Complutense University of Madrid, Madrid, Spain. emmarco@bio.ucm.es

Copyright

(Copyright © 2012, SAGE Publishing)

DOI

10.1177/0269881111408459

PMID

21693551

Abstract

Alterations in emotion regulation processes may form the basis of psychopathologies. The endocannabinoid (eCB) system, composed of endogenous ligands, the enzymatic machinery in charge of their metabolism and the specific metabotropic receptors, has emerged as a major neuromodulatory system critically involved in the control of emotional homeostasis and stress responsiveness. Data from animal models indicate that the eCB system plays a key role in brain development, and is probably involved in the control of emotional states from early developmental stages. The present review summarizes the latest information on the role of the eCB system in emotionality and anxiety-related disorders throughout the lifespan. Putative therapeutic strategies based on the pharmacological modulation of this system will be discussed. Given the fact that the pharmacological modulation of the eCB system has recently arisen as a promising strategy in the management of anxiety and mood disorders, the potential efficacy of this pharmacological approach (i.e. blockers of the catabolic pathway) will be discussed, as well as pharmacological alternatives such as modulators of cannabinoid receptors other than the classical CB1 receptor, or administration of other plant-derived compounds (e.g. cannabidiol).

Language: en